Trial Profile
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Cetrelimab (Primary) ; Erdafitinib (Primary) ; Carboplatin; Cisplatin
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NORSE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 06 Dec 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 06 Dec 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 05 Dec 2023 Planned End Date changed from 31 May 2024 to 30 Jun 2025.